MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-Hara T, Uchibori K, Subat-Motoshi S, Ninomiya H, Takeuchi K, Nishio M, Miyazaki Y, Katayama R.
Kondo N, et al. Among authors: takemoto a.
JCI Insight. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688.
JCI Insight. 2023.
PMID: 37917191
Free PMC article.